{"product_id":"ovid-vrio-analysis","title":"Ovid Therapeutics Inc. (OVID): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the core of Ovid Therapeutics Inc. (OVID)'s enduring success by dissecting its key resources through the rigorous VRIO framework. Is their current competitive edge truly sustainable, resting on assets that are Valuable, Rare, Inimitable, and Organized to capture opportunity? Dive into this essential analysis below to unlock the secrets behind Ovid Therapeutics Inc. (OVID)'s market position and see exactly where their true, defensible advantage lies.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: OV329 (GABA-AT Inhibitor) Clinical Profile \u0026amp; Data\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a drug candidate, OV329, that just put up strong Phase 1 numbers, suggesting it could be a real step up from older treatments for drug-resistant epilepsy. Honestly, the data from the December 2025 AES presentation is what matters now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Differentiated Efficacy and Safety Profile\u003c\/h3\u003e\n\u003cp\u003eOV329 provides a potential best-in-class treatment for drug-resistant seizures by offering a differentiated, potentially superior safety profile compared to older drugs like vigabatrin. The Phase 1 data showed robust target engagement. Specifically, the \u003cstrong\u003e5-mg\u003c\/strong\u003e dose increased long-interval intracortical inhibition (LICI 150 ms) by \u003cstrong\u003e53%\u003c\/strong\u003e (P = 0.0001) in the APB muscle, which exceeds the roughly \u003cstrong\u003e35%\u003c\/strong\u003e LICI increase reported for therapeutic doses of vigabatrin (2–3 g). Also, OV329 boosted mean GABA levels in the medial parietal lobe by \u003cstrong\u003e7.13%\u003c\/strong\u003e after seven days, versus only \u003cstrong\u003e0.24%\u003c\/strong\u003e for placebo. Crucially, the study reported no clinically significant ophthalmologic changes, a major issue with vigabatrin. That’s a tangible value proposition right there.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Potency and Mechanism\u003c\/h3\u003e\n\u003cp\u003eThe specific preclinical potency and differentiated mechanism suggest rarity. Preclinical characterization indicated that OV329 is potentially \u003cstrong\u003e100- to 1,000-fold\u003c\/strong\u003e more potent than vigabatrin in animals. This level of potency, combined with a mechanism designed to avoid the ocular accumulation seen with its predecessor, makes this profile hard to find. The drug is a selective inhibitor of GABA-aminotransferase (GABA-AT), increasing brain GABA levels to reduce neuronal hyperexcitability.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Validation Hurdles\u003c\/h3\u003e\n\u003cp\u003eReplicating OV329 is difficult; it requires replicating the specific molecular design and, more importantly, validating the positive Phase 1 safety and biomarker data seen in 2025. Any competitor would need to match the \u003cstrong\u003e53%\u003c\/strong\u003e LICI increase seen at the \u003cstrong\u003e5-mg\u003c\/strong\u003e dose and demonstrate a similarly clean ocular safety profile. The complexity lies in the full package: potency, target engagement across multiple TMS biomarkers, and rapid tissue clearance.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Clear Development Path\u003c\/h3\u003e\n\u003cp\u003eThe organization appears high; Ovid Therapeutics Inc. is clearly prioritizing this asset. They are supported by recent capital raising, with a private placement expected to extend the cash runway into the \u003cstrong\u003e2H 2028\u003c\/strong\u003e. The clear next step is the planned initiation of a Phase 2a randomized, placebo-controlled trial in adults with drug-resistant focal onset seizures in \u003cstrong\u003eQ2 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHere’s a quick look at the key data points supporting the current assessment:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eOV329 (5 mg Dose)\u003c\/th\u003e\n\u003cth\u003eVigabatrin (Therapeutic Dose)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLICI Increase (APB Muscle)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e~\u003cstrong\u003e35%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedial Parietal GABA Change (7 Days)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+7.13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Study Size (Total Participants)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e68\u003c\/strong\u003e healthy adults\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 2a Initiation Plan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ2 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage: Conditional Sustained Advantage\u003c\/h3\u003e\n\u003cp\u003eThe advantage is currently temporary, but it becomes \u003cstrong\u003eSustained\u003c\/strong\u003e, if the Phase 2a results in \u003cstrong\u003emid-2027\u003c\/strong\u003e confirm the differentiation seen in Phase 1. If the efficacy holds up in patients and the superior safety profile remains intact, Ovid will have a truly differentiated asset in a market needing better options. If onboarding for Phase 2a takes longer than expected, say past Q3 2026, the timeline for confirming this advantage slips, increasing execution risk.\u003c\/p\u003e\n\u003cp\u003eFinance: update the 13-week cash flow model to reflect the \u003cstrong\u003e$175 million\u003c\/strong\u003e private placement proceeds by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: KCC2 Direct Activator Platform Technology\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eOffers a first-in-class approach to restore inhibitory balance in the brain, applicable across multiple neurological and neuropsychiatric disorders.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlatform includes OV350, the first-in-human KCC2 direct activator.\u003c\/li\u003e\n\u003cli\u003ePlatform includes OV4071, the first oral KCC2 direct activator.\u003c\/li\u003e\n\u003cli\u003eAdvancing multiple oral and injectable KCC2 activator programs from its proprietary library.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eVery high; direct activation of the KCC2 transporter is a long-sought, difficult-to-target biological mechanism.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCandidate\u003c\/th\u003e\n\u003cth\u003eFormulation\u003c\/th\u003e\n\u003cth\u003eStatus\/Milestone\u003c\/th\u003e\n\u003cth\u003eExpected Timing\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV350\u003c\/td\u003e\n\u003ctd\u003eIV\u003c\/td\u003e\n\u003ctd\u003ePhase 1 SAD\/MAD Study Completion\/Results\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV4071\u003c\/td\u003e\n\u003ctd\u003eOral\u003c\/td\u003e\n\u003ctd\u003eIND-enabling studies completing \/ Phase 1 Initiation\u003c\/td\u003e\n\u003ctd\u003eQ2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eVery difficult; requires deep, proprietary knowledge in transporter biology and a library of validated compounds like OV350 and OV4071.\u003c\/p\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eHigh; the company has structured its pipeline to build a franchise around this platform, with multiple candidates advancing.\u003c\/p\u003e\n\u003cp\u003eCash, cash equivalents and marketable securities as of March 31, 2025 totaled \u003cstrong\u003e$43.0 million\u003c\/strong\u003e, expected to fund operations into 2H 2026.\u003c\/p\u003e\n\u003cp\u003eAs of June 30, 2025, cash, cash equivalents and marketable securities were \u003cstrong\u003e$38.3 million\u003c\/strong\u003e, expected into early 2H 2026.\u003c\/p\u003e\n\u003cp\u003eThe company announced a private placement of up to \u003cstrong\u003e$175 million\u003c\/strong\u003e in gross proceeds, with an initial closing of approximately \u003cstrong\u003e$81 million\u003c\/strong\u003e, expected to extend the anticipated cash runway into 2H 2028.\u003c\/p\u003e\n\u003c\/h\u003e\u003ch\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003ch\u003e\n\u003cp\u003eSustained; this platform technology is a significant barrier to entry for competitors.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe KCC2 portfolio offers successive programs.\u003c\/li\u003e\n\u003cli\u003eThe platform has differentiated potential with unique target.\u003c\/li\u003e\n\u003cli\u003eThe platform provides strategic optionality to collaborate or out-license.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/h\u003e\u003ch\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: OV350 (KCC2 IV) Near-Term Data Catalyst\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe expected Q4 2025 topline Phase 1 findings for this intravenous candidate are a crucial, near-term value inflection point for the entire KCC2 franchise. Preclinical data showed OV350 in combination with diazepam terminated seizures and restored efficacy of diazepam in an acute seizure model.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nPhase 1 data is common, but first-in-human data for a direct KCC2 activator is rare. The KCC2 portfolio was exclusively in-licensed from AstraZeneca in 2022.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nEasy to imitate the process of running a Phase 1 trial, but impossible to replicate the specific data generated.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nHigh; the organization is clearly focused on hitting this 2025 milestone to de-risk the oral candidate, OV4071.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOV350 Phase 1 dosing in healthy volunteers initiated in Q1 2025.\u003c\/li\u003e\n\u003cli\u003eOV4071 (Oral KCC2 direct activator) anticipates Phase 1 initiation in Q2 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMilestone\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003cth\u003eStatus\/Result\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV350 Phase 1 Dosing Start\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eInitiated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV350 Phase 1 Topline Data (Safety\/PK)\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003ctd\u003eAnticipated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV4071 Phase 1\/1b Start\u003c\/td\u003e\n\u003ctd\u003eQ2 2026\u003c\/td\u003e\n\u003ctd\u003eAnticipated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eInto 2H 2028\u003c\/td\u003e\n\u003ctd\u003ePost up to \u003cstrong\u003e$175 million\u003c\/strong\u003e financing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nFinancial position as of June 30, 2025, included cash, cash equivalents and marketable securities of $38.3 million.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary; this advantage lasts only until the data is released, after which the focus shifts to the next milestone.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: Extended Cash Runway into 2H 2028\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides operational stability, allowing management to focus on clinical execution rather than constant emergency fundraising.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; many clinical-stage biotechs struggle with short runways, but the \u003cstrong\u003e$175 million\u003c\/strong\u003e October 2025 PIPE was significant. The initial closing brought in approximately \u003cstrong\u003e$81 million\u003c\/strong\u003e in upfront capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEasy; competitors can raise capital, but the timing and amount achieved here are specific to Ovid Therapeutics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the successful execution of the October 2025 private placement shows financial discipline and investor confidence. The financing attracted participation from Janus Henderson Investors, RA Capital Management, and Eventide Asset Management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; the runway is finite, ending in the second half of 2028, requiring future financing or positive data.\u003c\/p\u003e\n\u003cp\u003eFinancial Context of the Extended Runway:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Date\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Gross Proceeds Expected (PIPE)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$175 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOctober 2025 financing agreement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Gross Proceeds Received\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$81 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eInitial closing of the October 2025 PIPE.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End Date\u003c\/td\u003e\n\u003ctd\u003eInto the \u003cstrong\u003esecond half of 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on initial proceeds plus existing cash.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents (June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrior to the October 2025 financing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Additional Proceeds (Warrants)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$94.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIf Series A and Series B warrants are fully exercised for cash.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrant Exercise Price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.40\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003ctd\u003eApplicable to Series A and Series B warrants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey Financial Metrics Supporting Liquidity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDebt-to-Equity Ratio: \u003cstrong\u003e0.25\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Debt: \u003cstrong\u003e$0\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCurrent Ratio: \u003cstrong\u003e4.72\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: Intellectual Property Protection for OV329\n\u003c\/h2\u003e\n\u003cp\u003eThe intellectual property surrounding Ovid Therapeutics' lead asset, OV329, is a core component of its potential commercial viability.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe intellectual property secures the potential market exclusivity for OV329, which is critical for future commercial returns, particularly as the company reported a net loss of \u003cstrong\u003e$26.4 million\u003c\/strong\u003e for the full year 2024.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe IP position includes \u003cstrong\u003emultiple patent families\u003c\/strong\u003e directed to the synthesis of OV329 and methods of treatment with OV329. The composition of matter patent for OV329 is set to expire in \u003cstrong\u003e2036\u003c\/strong\u003e, excluding any potential regulatory extensions.\u003c\/p\u003e\n\n\u003cp\u003eContextual financial and IP data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV329 Composition of Matter Patent Expiry\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2036\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExcluding potential regulatory extensions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV329 Related Patent Families\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMultiple\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDirected to synthesis and methods of treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$53.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eCompetitors face difficulty in designing around the existing composition-of-matter patents for OV329.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe intellectual property strategy is integrated with the development plan, aiming to protect the asset through its expected commercial life, which is supported by a cash runway expected into the second half of 2026 as of December 31, 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOV329 Phase 1 Topline Readout anticipated in \u003cstrong\u003eQ3 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential initiation of a Phase 2a patient study for OV329 in drug-resistant epilepsies anticipated in \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is expected to be sustained, contingent upon the patents remaining valid and enforceable throughout the exclusivity period ending in \u003cstrong\u003e2036\u003c\/strong\u003e for the core composition of matter.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: Veteran Neuroscience Management Team\n\u003c\/h2\u003e\n\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eReduces execution risk by having leaders who have collectively developed and commercialized over \u003cstrong\u003e25\u003c\/strong\u003e medicines in the relevant therapeutic areas.\u003c\/p\u003e\n\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; deep, relevant experience in CNS\/rare diseases is valuable but not unique in the sector.\u003c\/p\u003e\n\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDifficult; this specific collective experience and established network cannot be hired overnight.\u003c\/p\u003e\n\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; evidenced by the smooth planned transition to Meg Alexander, showing continuity in strategy. Meg Alexander, who joined in \u003cstrong\u003e2021\u003c\/strong\u003e, will assume the role of CEO effective \u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e, succeeding co-founder Dr. Jeremy M. Levin, who transitions to Executive Chair.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAttribute\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollective Medicine Launches\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOver 25\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver the last twenty years across large biotech\/pharma.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTeam Composition Detail\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFive\u003c\/strong\u003e individuals with M.D. degrees and \u003cstrong\u003e13\u003c\/strong\u003e professionals with Ph.D. degrees specializing in the sciences.\u003c\/td\u003e\n\u003ctd\u003eAs of March 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO Transition Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJanuary 1, 2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMeg Alexander appointed CEO.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CEO Tenure at OVID\u003c\/td\u003e\n\u003ctd\u003eSince \u003cstrong\u003e2021\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eMeg Alexander joined Ovid in 2021.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the three months ended September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash as of Q3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash, cash equivalents, and marketable securities as of September 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent Financing Gross Proceeds\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$175 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCompleted private placement, with an initial closing of approximately \u003cstrong\u003e$81 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Cash Runway Extension\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2H 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExpected funding period based on recent financing and cash on hand.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (at announcement)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$96 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported at the time of the leadership announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003e\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained; team experience is a long-term, hard-to-replicate asset.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe team has been heavily involved in, or led, the launch of modern anti-seizure medicines.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe pipeline includes \u003cstrong\u003ethree\u003c\/strong\u003e active programs: OV329, OV350 (KCC2 activator), and OV888\/GV101 (ROCK2 inhibitor).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eFirst-in-human data for OV350 expected in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e; first oral KCC2 activator, OV4071, anticipated to enter clinic in \u003cstrong\u003eQ2 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: Strategic Asset Monetization Capability\n\u003c\/h2\u003e\n\u003cp\u003eThe Strategic Asset Monetization Capability is assessed based on the definitive agreement with Immedica Pharma AB for the sale of future royalties related to ganaxolone sales outside of China, announced on June 25, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe monetization generated a direct, non-dilutive capital infusion to fund core pipeline operations. The transaction provided \\$7 million in cash. This is contrasted with the \\$566,000 in ganaxolone royalty revenues recorded by Ovid in 2024.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Infusion from Royalty Sale\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 2025 Agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGanaxolone Royalty Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$566,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Royalty Agreement Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$6.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$38.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; the successful divestiture of non-core asset royalties for favorable terms is not common across the sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; the specific asset (future royalties on ganaxolone outside China) is unique to Ovid's prior licensing history, but the structure of finding a buyer like Immedica Pharma AB is repeatable for other firms with similar non-core IP.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the company demonstrated organizational alignment by executing the sale of non-core IP (as Ovid was not pursuing ganaxolone development) to extend its operational runway, with cash, cash equivalents and marketable securities of \\$38.3 million as of June 30, 2025, expected to support operations into early 2H 2026.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe agreement included the sale of 100% of the royalty rights held by Ovid.\u003c\/li\u003e\n\u003cli\u003eImmedica also agreed to acquire or license the global ganaxolone intellectual property (IP) portfolio from Ovid.\u003c\/li\u003e\n\u003cli\u003eImmedica will assume financial responsibility for all costs related to the licensed IP upon final amendment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; this advantage is contingent upon the existence of non-core, monetizable assets like the ganaxolone royalties.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: Pipeline Focus on Neural Excitatory\/Inhibitory Balance\n\u003c\/h2\u003e\n\u003cp\u003eThe core strategy centers on developing small molecule medicines to restore neural excitatory\/inhibitory balance in CNS disorders.\u003c\/p\u003e\n\n\u003ch5\u003eValue\u003c\/h5\u003e\n\u003cp\u003eConcentrates R\u0026amp;D efforts on a validated biological principle (restoring balance) across multiple indications, increasing the probability of success across the portfolio.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOV329, a next-generation GABA-AT inhibitor, targets treatment-resistant seizures and other undisclosed indications.\u003c\/li\u003e\n\u003cli\u003eThe KCC2 direct activator portfolio (OV350, OV4071) targets restoration of inhibitory tone in the brain.\u003c\/li\u003e\n\u003cli\u003eOV329 Phase 1 topline results anticipated in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch5\u003eRarity\u003c\/h5\u003e\n\u003cp\u003eModerate; many biotechs focus on a single target, but Ovid Therapeutics has two distinct, validated approaches (GABA-AT and KCC2).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMechanism\u003c\/th\u003e\n\u003cth\u003eStatus\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV329\u003c\/td\u003e\n\u003ctd\u003eGABA-AT Inhibitor\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Study; DREs indication potential.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV350\u003c\/td\u003e\n\u003ctd\u003eKCC2 Direct Activator (IV)\u003c\/td\u003e\n\u003ctd\u003ePhase 1 Study; First-in-human data expected Q4 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV4071\u003c\/td\u003e\n\u003ctd\u003eKCC2 Direct Activator (Oral)\u003c\/td\u003e\n\u003ctd\u003eIND-enabling studies completing; Human trials anticipated Q2 2026.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch5\u003eImitability\u003c\/h5\u003e\n\u003cp\u003eDifficult; requires the specific scientific insight to apply these mechanisms across different CNS disorders effectively.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOV329 seeks to reduce hyperexcitability with less sedation and without ocular changes associated with vigabatrin.\u003c\/li\u003e\n\u003cli\u003eThe KCC2 portfolio is designed to build a first-in-class franchise.\u003c\/li\u003e\n\u003cli\u003eOV4071 is described as the first-ever oral KCC2 direct activator.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch5\u003eOrganization\u003c\/h5\u003e\n\u003cp\u003eHigh; the entire pipeline, from OV329 to OV4071, is aligned under this core scientific thesis.\u003c\/p\u003e\n\u003cp\u003eFinancial resources support this alignment, with a recent capital raise extending the operational timeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents and marketable securities as of September 30, 2025: $25.6 million.\u003c\/li\u003e\n\u003cli\u003eAnticipated cash runway extension into 2H 2028 following a private placement of up to $175 million gross proceeds.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Research and development expenses: $5.9 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch5\u003eCompetitive Advantage\u003c\/h5\u003e\n\u003cp\u003eSustained; this foundational scientific focus provides a consistent strategic direction.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest Reported Value\u003c\/th\u003e\n\u003cth\u003ePeriod End Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2024 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$26.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.3 million\u003c\/strong\u003e (Implied from Q3 2025 data, using $14.0M loss from Q3 2024 as a reference point for context, but using the latest available data structure)\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFull Year 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$566,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOV329 Phase 2a Initiation Target\u003c\/td\u003e\n\u003ctd\u003eQ1 2026 (Previously) \/ Q2 2026 (Latest)\u003c\/td\u003e\n\u003ctd\u003e2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eOvid Therapeutics Inc. (OVID) - VRIO Analysis: OV4071 (Oral KCC2 Activator) Advancement Potential\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOV4071 (Oral KCC2 Activator) Advancement Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Represents the oral formulation potential of the KCC2 platform, which is crucial for broader market access and patient convenience in indications like Parkinson's psychosis.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; an oral KCC2 activator is a significant step beyond the IV candidate (OV350) and is rare in development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires successfully navigating the IND submission planned for \u003cstrong\u003eQ1 2026\u003c\/strong\u003e and subsequent clinical trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company is clearly leveraging the OV350 data to inform the advancement of OV4071.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, provided they achieve the \u003cstrong\u003eQ2 2026\u003c\/strong\u003e Phase 1 initiation and positive PoC results in \u003cstrong\u003eQ1 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e draft the 2026 capital expenditure budget based on the 2028 runway projection by next Tuesday.\u003c\/p\u003e\n\u003cp\u003eThe financial context supporting the pipeline advancement is anchored by a recent capital raise and current cash position.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway (Post Financing)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2H 2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost Private Placement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway (Pre-Financing)\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003e2H 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Nine Months Ended Sept 30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional Ownership\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e72.24%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLate 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey anticipated milestones for the KCC2 direct activator portfolio:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOV350 (IV KCC2 direct activator) Topline Safety, Tolerability, and PK Data: \u003cstrong\u003eQ4 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOV329 Phase 2a Patient Study Initiation (Drug-Resistant Epilepsies): \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOV4071 Regulatory Submission (IND): \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOV4071 Phase 1\/1b Study Initiation (Healthy Volunteer\/Patient Cohorts): \u003cstrong\u003eQ2 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOV4071 Phase 1b Studies Initiation (PD Psychosis, LBD): Projected \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOV4071 Ketamine Challenge Study Initiation: Projected \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516226298005,"sku":"ovid-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ovid-vrio-analysis.png?v=1740203365","url":"https:\/\/dcf-model.com\/products\/ovid-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}